(Press-News.org) Each year, more than 25,000 Americans are diagnosed with multiple myeloma, a form of blood cancer that often develops resistance to therapies. However, researchers at Virginia Commonwealth University Massey Cancer Center are reporting promising results from laboratory experiments testing a new combination therapy that could potentially overcome the resistance hurdle.
While several drugs are effective against multiple myeloma, including the proteasome inhibitor bortezomib, multiple myeloma cells are often able to survive by increasing the production of a protein known as Mcl-1. Mcl-1 regulates a number of processes that promote cell survival and has been implicated in resistance to anti-myeloma drugs that were initially effective. However, a team of researchers led by Xin-Yan Pei, M.D., Ph.D., and Steven Grant, M.D., recently published the findings of a study in the journal PLoS ONE demonstrating that a novel drug combination both reduces Mcl-1 expression and disrupts its interactions with other proteins to effectively kill multiple myeloma cells. The therapy combines a type of drug known as a Chk1 inhibitor with another called a MEK inhibitor. Chk1 inhibitors prevent cells from arresting in stages of the cell cycle that facilitate the repair of DNA damage, while MEK inhibitors prevent cells from activating a variety of proteins that regulate DNA repair processes while promoting the accumulation of pro-death proteins.
"This research builds on our previous studies that showed exposing multiple myeloma and leukemia cells to Chk1 inhibitors activated a protective response through the Ras/MEK/ERK signaling pathway," says Pei, instructor in the Department of Internal Medicine at the VCU School of Medicine. "By combining a Chk1 inhibitor with a MEK inhibitor, we have developed one of only a limited number of strategies shown to circumvent therapeutic resistance caused by high expressions of Mcl-1."
In laboratory experiments, the scientists enforced overexpression of Mcl-1 in human multiple myeloma cells. They found that this caused the cells to become highly resistant to bortezomib, but it failed to protect them from the Chk1/MEK inhibitor regimen. Additionally, the combination therapy was able to completely overcome resistance due to microenvironmental factors associated with increased expression of Mcl-1. A cell's microenvironment consists of surrounding cells and the fluids in which they reside, and the communication between cancer cells and their surrounding cells can significantly impact resistance. Mcl-1 plays a key role in this communication by facilitating events that promote cancer cell survival.
"Not only was the combination therapy effective against multiple myeloma cells, it notably did not harm normal bone marrow cells, raising the possibility of therapeutic selectivity," says Grant, the study's lead investigator and Shirley Carter Olsson and Sture Gordon Olsson Chair in Cancer Research, associate director for translational research and program co-leader of Developmental Therapeutics at VCU Massey Cancer Center. "We are hopeful that this research will lead to better therapies for multiple myeloma, and help make current therapies more effective by overcoming resistance caused by Mcl-1."
The researchers have started initial discussions with clinical investigators and drug manufacturers with hopes of developing a clinical trial testing a combination of Chk1 and MEK inhibitors in patients with refractory multiple myeloma. It is too early to estimate when the trial will open.
INFORMATION:
In addition to Pei, Grant collaborated on this study with Yun Dai, MD., Ph.D., Shuang Chen, M.D., Ph.D, Leena E. Youssefian, Weslie W. Bodie, Yukie Takabatake, Jessica Felthousen, Jorge A. Almenara, Ph.D., Lora B. Kramer, Liang Zhou, and Michael Sanderson, all from the Division of Hematology, Oncology and Palliative Care at the VCU School of Medicine, and Robert Orlowski, M.D., Ph.D., from M.D. Anderson Cancer Center.
This research was supported by awards CA100866, CA93738 and P50 CA142509-01 from the National Institutes of Health, the Multiple Myeloma Research Foundation, a Multiple Myeloma SPORE award and, in part, by Massey's National Cancer Institute Cancer Center Support Grant P30CA016059.
The full manuscript of this study is available online at: http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0089064
News directors: Broadcast access to VCU Massey Cancer Center experts is available through VideoLink ReadyCam. ReadyCam transmits video and audio via fiber optics through a system that is routed to your newsroom. To schedule a live or taped interview, contact Alaina Schneider, (804) 628-4578.
About VCU Massey Cancer Center
VCU Massey Cancer Center is one of only 68 National Cancer Institute-designated institutions in the country that leads and shapes America's cancer research efforts. Working with all kinds of cancers, the Center conducts basic, translational and clinical cancer research, provides state-of-the-art treatments and clinical trials, and promotes cancer prevention and education. Since 1974, Massey has served as an internationally recognized center of excellence. It offers the most cancer clinical trials in Virginia and serves patients at 10 locations. Its 1,000 researchers, clinicians and staff members are dedicated to improving the quality of human life by developing and delivering effective means to prevent, control and ultimately to cure cancer. Visit Massey online at http://www.massey.vcu.edu or call 877-4-MASSEY for more information.
About VCU and the VCU Medical Center
Virginia Commonwealth University is a major, urban public research university with national and international rankings in sponsored research. Located in downtown Richmond, VCU enrolls more than 31,000 students in 222 degree and certificate programs in the arts, sciences and humanities. Sixty-six of the programs are unique in Virginia, many of them crossing the disciplines of VCU's 13 schools and one college. MCV Hospitals and the health sciences schools of Virginia Commonwealth University compose the VCU Medical Center, one of the nation's leading academic medical centers. For more, see http://www.vcu.edu.
New combination therapy developed for multiple myeloma
2014-05-01
[Attachments] See images for this press release:
ELSE PRESS RELEASES FROM THIS DATE:
Scientists figure out staying power of HIV-fighting enzyme
2014-05-01
Johns Hopkins biochemists have figured out what is needed to activate and sustain the virus-fighting activity of an enzyme found in CD4+ T cells, the human immune cells infected by HIV. The discovery could launch a more effective strategy for preventing the spread of HIV in the body with drugs targeting this enzyme, they say. A summary of their work was published online on April 21 in the journal Proceedings of the National Academy of Sciences.
"Current antiretroviral drugs target HIV's proteins," says James Stivers, Ph.D., a professor of pharmacology and molecular sciences ...
Implementation science can create a workforce equipped for new health care environment
2014-05-01
INDIANAPOLIS -- The new Center for Health Innovation & Implementation Science at the Indiana University School of Medicine and Indiana Clinical and Translational Sciences Institute is studying how best to prepare the future health care workforce as the country's population ages. It calls upon the tools of implementation science to enable these workers and the health systems that will employ them to provide optimal care in a rapidly changing health care environment.
Implementation science, a new discipline, provides tools to clinicians and administrators to deliver better ...
Hyperfractionated RT improves local-regional control for patients with head and neck cancer
2014-05-01
Fairfax, Va., May 1, 2014—Patients with locally advanced squamous cell carcinoma of the head and neck treated with hyperfractionated radiation therapy (HFX) experienced improved local-regional control and, with patients censored at five years, improved overall survival with no increase in late toxicity, according to a study published in the May 1, 2014 edition of the International Journal of Radiation Oncology ● Biology ● Physics (Red Journal), the official scientific journal of the American Society for Radiation Oncology (ASTRO).
This study, "Final Results ...
Clinical opinion published in American Journal of Obstetrics & Gynecology
2014-05-01
When a woman requires gynecologic surgery, she and her surgeon have several minimally invasive surgical options, including robotic surgery. In recent years, the use of robotic surgery has become more and more common. But questions have arisen about the potential overuse of robotic surgery and its advantages over traditional laparotomy for hysterectomy.
A clinical opinion by Charles Rardin, MD, a urogynecologist in the Division of Urogynecology and Reconstructive Surgery and director of the Robotic Surgery Program for Women at Women & Infants Hospital of Rhode Island, ...
Standard assessments miss early signs of cardiovascular disease in firefighters
2014-05-01
Traditional first-line checks of such heart disease risk factors as cholesterol, blood pressure and smoking habits aren't nearly good enough to identify cardiovascular disease in otherwise healthy, young firefighters, according to results of a small Johns Hopkins study.
Previous studies have found that cardiovascular disease accounts for 45 percent of deaths of on-duty firefighters nationwide, in contrast to 15 percent of deaths among those with conventional occupations, with heart attack being the number one cause of death. The Johns Hopkins researchers designed their ...
Amphibians in a vice: Climate change robs frogs, salamanders of refuge
2014-05-01
By hightailing it to nearby ponds and shallow waterways, frogs and salamanders have – until now – had a way to evade exotic trout introduced to the West's high-mountain lakes for recreational fishing.
A warming climate, however, will dry up some of the places where amphibians and their young have found refuge. Researchers in the May 1 issue of Frontiers in Ecology and the Environment write about this challenge and a novel combination of tools that could help land managers, biologists, fishing enthusiasts and other citizens weigh where amphibians are in the most need of ...
New discovery: Molecule links asthma and cancer and could aid in developing new treatments
2014-05-01
A newly discovered molecule provides a new drug target for controlling both asthma-induced muscle thickening and cancerous tumor growth. This molecule, called "microRNA-10a," normally helps genes produce proteins or make copies of themselves, also play an important role in the growth or overgrowth of human airway smooth muscle cells and some forms of cancer. This newly discovered role, which was published in the May 2014 issue of The FASEB Journal, suggests that manipulating microRNA-10a could lead to new asthma and cancer drugs.
"We hope this study will serve as the ...
Killing Kindlin-3 to cure breast cancer: 'Blood' protein implicated
2014-05-01
A protein believed to be limited to the hematopoietic system, called Kindlin-3, has been identified as a major player in both the formation and spread of breast cancer to other organs. This discovery, published in the May 2014 issue of The FASEB Journal, could open the door to an entirely new class of breast cancer drugs that targets this protein's newly found activity.
"Kill Kindlin-3 to cure cancer," said Elzbieta Pluskota, Ph.D., a researcher involved in the work from the Department of Molecular Cardiology at the Cleveland Clinic Lerner Research Institute in Cleveland, ...
Monitoring, management, and oversight critical for responsible shale gas development
2014-05-01
Ottawa (May 1st, 2014) – A new expert panel report, Environmental Impacts of Shale Gas Extraction in Canada, concludes that shale gas development must be supported by well-targeted science and management strategies to understand and mitigate potential impacts. The report, released today by the Council of Canadian Academies, addresses environmental and associated health impacts and offers insights regarding public engagement and trust.
Shale gas is leading an energy boom which is having profound economic, environmental, and social impacts across much of North America. ...
Rules of thumb: 3 simple ideas for overcoming childhood obesity
2014-05-01
New Orleans, LA – Kristopher Kaliebe, MD, Clinical Assistant Professor of Psychiatry at the LSU Health Sciences Center New Orleans School of Medicine, offers parents and caregivers three simple family-oriented goals to overcome the complex problem of childhood obesity and related mental disorders. They involve limit setting to address the brain's "get more" drive strengthened through habitual over-consumption of temptations including highly caloric processed food, hyper-reality media and electronics, as well as excessive sitting. His 3 "rules" of living promote physical ...